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Teratogenicity is the most serious manifestation of iatrogenic fetal toxicity: teratogens lead to 3 fetal malformation and are implicated in lifelong physical and/or mental disabilities 1 . 4 Nonetheless, clinical trial results of drug exposure during pregnancy are often conflicting 2-4 , and 5 teratogenicity scoring for small molecules is unsystematic and performed outside the clinical 6 environment [5] [6] [7] . The consequences of this subjectivity are seen in the high rate of unintended 7 maternal exposure to a teratogenic agent 8 , reminiscent of the "thalidomide disaster" of the early 8 1960s 9, 10 . Following this disaster, randomized, controlled trials (RCTs) were modified to exclude 9 pregnant populations, fearing unintended teratogenicity from exposure to unsystematically 10 profiled drugs 10 . This change continues to "orphan" pregnant women, as many diseases in 11 women's health lack safe and effective drug choices for treatment 8,11,12 . 12 In the wake of the "thalidomide disaster," the United States Food and Drug Administration 13 (FDA) developed a five-point scale for ranking the teratogenicity of a compound [7] [8] [9] 11 . This scale 14 is presented in 16 A hallmark of the binning within this scale is the absence of definitive human data: at present, 17 teratogenicity scores are established pre-clinically by pharmacologists, who evaluate biomarkers 18 of fetal toxicity in animal models 5, 6 . This approach is inherently limited, as common in vivo 19 models are not sufficiently representative of human physiology 13 , and human subjects are not 20 included in the teratogenicity scoring process for ethical reasons 11, 14, 15 . Indeed, the limited 21 human data available for teratology scoring are often derived retrospectively from high-profile 22 cases of fetal malformation resulting from drug exposure 9, 16, 17 . While new FDA standards for 23 scoring teratogenicity acknowledge these limitations by providing fewer, more holistic toxicity 1 scores, these standards still suffer from the absence of robust human data and are not yet 2 integrated in clinical decision-making tools 18 . 3 Collectively, the factors above create a significant degree of uncertainty at the point of care 4 (POC), as providers are guided on contradictory, incomplete, and non-human derived 5 information in their choice of prescriptions for pregnant women. This dilemma is of special 6 consequence to expectant mothers with chronic morbidities pre-existing to their pregnancies 11 . 7 8 Fetal exposure to a teratogen in utero strongly associates with cognitive and/or physical 9 disabilities, resulting from dysregulation of key developmental processes such as neurulation, 10 purine and pyrimidine synthesis, and lipid anabolism 2, 19 .
Target rationale for teratogenesis
11
Broadly, teratogens may be categorized by their mechanism of action (MOA) as either "on-
12
target" or "off-target [20] [21] [22] ." "On-target" teratogenicity implies the generation of adverse 13 phenotypes from bioactive agents impacting well-defined protein targets that are critically 14 regulated in development. In contrast, "off-target" teratogenicity implies mutagenicity, resulting 15 from DNA damage such as alkylation and thymine dimerization. "Off-target" teratogenicity 16 involves repeated reactions between a teratogen and newly-synthesized nucleic acid residues, 17 often resulting from the generation of reactive oxygen species (ROS) generated from drug 18 metabolism 20 . 19 Thus, teratology is known to converge on few principal MOA classes 19, 23 , which are outlined in 20 18 16,000 resulting articles revealed strong association of the term "teratogenic" with a mention of 19 FDA scores C, D, and X. Therefore, this binary scale was defined by "Non-Teratogenic" (scores 20 A/B) and "Teratogenic" (scores C/D/X) classes. Discussion" section.
4
Noting that multiple structure-teratogenicity relationships resulting from our t-SNE analysis were 5 validated in the literature, we considered our unsupervised ML model to be a successful proof-6 of-concept experiment. This-along with meaningful multiclass ROC analysis for structure- 
Supervised modeling
11
Given that t-SNE successfully and consistently identified moieties that might predispose a drug 12 towards an increased risk of teratogenicity, we decided to enable a supervised ML model that can 13 prospectively predict a drug's teratogenicity score from structural information. Using the R 14 package Caret (CRAN: Caret)
59
, we developed three (3) models with inherent five (5) Given that teratogenicity has well-identified target rationale, we decided to leverage existing, 12 real-world bioassay information for all targets implicated in teratogenesis (as described We found that drug structure is a good predictor of teratogenicity, as multiclass ROC analysis 10 between 1,024-dimensional Morgan fingerprints and a three-pronged teratogenicity metric gave 11 AUC = 0.78 ( Figure 1 ). This result validates our hypothesis that a "form-fits-function" argument 12 is valid for predicting teratogenicity from homology between drug structure and pharmacophore 13 biochemistry among targets implicated in teratogenesis.
[INSERT FIGURE 1 HERE] 15
From t-SNE analysis between drug structure and a binary encoding of teratogenicity (Figure 2 ), 16 we discovered clusters of teratogenic risk and the absence thereof, which are partially validated behavior may involve dimensionality mismatch between structure and teratogenicity data sets, 21 given that we plotted 1,024 structural motifs against only two (2) teratogenicity scores. Beyond these validated associations, we also discovered new structure-teratogenicity identity-which is non-teratogenic-it is reasonable to assert that the azetidinone functionality 15 and dihydrothiazine ring are non-teratogenic chemomarkers in this case. We recognize that the 16 burden of evidence is significant to claim that these motifs demonstrate protective effects.
17
Instead, we suggest that our results warrant more involved analysis of these potentially protective 18 moieties. 19 In contrast, similar analysis of "YES" clusters reveals three teratogenic chemomarkers, including 20 corticosteroids, fluoroquinolones, and acetylproline derivatives. While fluoroquinolones are 21 documented teratogens [75] [76] [77] [78] , there is contention on the toxicity of steroid derivatives 79-81 , as well 22 as prolinated compounds [82] [83] [84] . Our model adds to this discussion by arguing that steroid 23 derivatives are indeed teratogenic. 24 We reasonably assume that the "YES" functionalities in Figure 3 are the source of teratogenicity 1 within molecules that contain them, given that these moieties are distinctive. in Figure 1 , this intersection remains small: only two (2) targets have coverage through Tox21. 4 Therefore, though real-world bioactivity information is inherently powerful, we were able to 5 access data on only two (2) given the inherently limited data resources currently existing available and little action on the 11 part of data providers to address these quality issues. the rigor of rules-based ML classification algorithms and limited "on-target" rationale for 5 teratogenesis, there is potential to systematically predict a compound's risk for fetal toxicity by 6 leveraging AI on drug-specific information, such as drug structure, meta-structure, and existing 7 real-world bioassay data, as a proxy for binding affinity to teratogenic targets.
8
In our study, we assert that drug structure is a good predictor of teratogenicity, using ROC 9 analysis, unsupervised ML (t-SNE), and a supervised GBM to discover relationships between 10 chemical functionalities within drugs prescriptible in pregnancy and existing teratogenicity 11 information. This allowed us to identify moieties that appear to predispose a drug towards an 12 increased chance of teratogenicity, based on existing use cases that are salient in relevant clinical 13 and drug development literature. We also identify significant barriers to translational research in 14 this space as rationale for the limited utility of existing meta-structural and toxicology HTS 15 platforms for teratogenicity prediction tasks. The importance of these ontological considerations 16 cannot be overstated in considering future research to improve the quality of data-driven 17 maternal-fetal medicine. 18 Our team of investigators has formed a first-in-kind research collaboration of engineers, 19 informaticians, and clinicians dedicated to the development of computational tools to predict to similar hits from QSAR. Indeed, drugs identified as teratogenic through MedWAS may be 12 referred to our QSAR model for validation, and vice versa. We have begun work on this 13 MedWAS and look forward to further exploring its intersections with our teratogenicity QSAR. interpret model results and reviewed this manuscript.
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We declare no competing interests relevant to the execution or outcomes of this study. COX-1 inhibition is associated with cardiac, midline, and diaphragm defects, as the release of prostaglandins required for healthy morphogenesis is reduced by interference within the COX-1 signaling pathway.
N-methyl-D -aspartate receptor (NMDAR)
NMDAR inhibition is associated with gross structural defects within the brain, resulting from dysregulation of neuronal migration, synapse formation, and synapse elimination in the developing fetus. 5-hydroxytryptamine (5-HT) receptor, 5-HT transporter 5-HT is a neurotransmitter critical to craniofacial morphogenesis in development. Agents activating or inhibiting 5-HT-or promoting 5-HT reuptake-disrupt a critical 5-HT concentration, resulting in craniofacial malformations and other structural defects in the fetus.
γ
-aminobutyric acid (GABA) receptor GABA is a key inhibitory neurotransmitter that guides healthy testicular, ovarian, pancreatic, enteric, and palatal morphogenesis at a critical concentration. Enhancers of GABA receptor are significantly associated in malformation of these tissues and are therefore implicated in morbidities such as cleft palate and atresia of the gastrointestinal This plot was generated using the R package Rtsne (CRAN: Rtsne) 102 .
Figure 3:
We discovered relationships between teratogenic risk ("YES", "NO") and the presence of distinct chemical functionalities from consistent structure-teratogenicity points within each discrete t-SNE cluster.
